MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Zafgen (Nasdaq: ZFGN)
Organization & Developments: Zafgen
Parents
Zafgen (Nasdaq: ZFGN)
Children
2018: Zafgen: This Revaluation And Catalyst Story Is Still In Early Innings
2019: Biotech Analysis Central Preview Series: Zafgen_ seekingalpha.com
2019: Zafgen Looks To Target Large Diabetes Market After Positive Mid-Stage Data - Zafgen, Inc. (NASDAQ:ZFGN)
DEVELOPING AN INJECTION FOR THE TREATMENT OF MULTIPLE INDICATIONS INCLUDING OBESITY AND HYPERPHAGIA.
Its lead drug, called beloranib, has been granted orphan drug designation in the U.S. for a rare genetic condition known as Prader-Willi, which causes severe obesity
The company ultimately plans to develop a drug for more common causes of obesity.
Jumps
*Key People: Zafgen
Finance & Acquisitions: Zafgen